posted on 2025-03-19, 15:08authored byVikas Upadhyay, Hongxiang Li, Jiachen He, Blake Edward Ocampo, Silas Cook, Huimin Zhao, Costas D. Maranas
The supply of artemisinin, the primary antimalarial drug
recommended
by the World Health Organization (WHO), is limited due to synthesis
cost and supply constraints. This study explores novel chemo-enzymatic
pathways for the efficient synthesis of dihydroartemisinic acid (DHAA),
the penultimate precursor to artemisinin. The key concept here is
to leverage the seamless integration of chemical and enzymatic steps
for more thoroughly exploring synthesis alternatives. Using novoStoic,
a biosynthetic pathway design tool, we identified previously unexplored
carbon- and energy-balanced pathways for converting amorpha-4,11-diene
(AMPD) to DHAA. For some of the enzymatically catalyzed steps lacking
efficient enzymes, chemical catalysis alternatives were proposed and
implemented, leading to a hybrid chemo-enzymatic pathway design. The
proposed pathway converts AMPD directly to DHAA without going through
artemisinic acid (AA), making it a shorter pathway compared with the
existing synthesis routes for artemisinin. This effort paves the way
for the systematic design of chemo-enzymatic pathways and provides
insight into decision strategies between chemical synthesis and enzymatic
synthesis steps. It serves as an example of how synthesis pathway
design tools can be integrated with human intuition for accelerating
retrosynthesis and how AI-based tools can identify and replace human
intuitions to automate the decision processes. This can help reduce
human-machine interventions and improve the development of future
tools for synthesis planning.